The University of Chicago Header Logo

The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.

The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. Future Oncol. 2024; 20(27):1983-1991.

View in: PubMed